newsfilter
← Earnings
Earnings Releases·

Design Therapeutics — Third Quarter 2026 Earnings Summary

Design Therapeutics reported a net loss of $20.3 million for the third quarter of 2026, with research and development expenses totaling $16.9 million and general and administrative expenses at $5.3 million. The company ended the quarter with $208.6 million in cash, cash equivalents, and investment securities, providing a strong financial runway. Key clinical programs include the ongoing RESTORE-FA trial for DT-216P2 in Friedreich ataxia, which is expected to provide registrational plan updates in Q4 2026 and 12-week data in Q1 2027. Additionally, trials for DT-818 in myotonic dystrophy type-1 and DT-168 in Fuchs endothelial corneal dystrophy are proceeding with data anticipated in 2027.

Company
DESIGN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology